JP2024542188A5 - - Google Patents

Info

Publication number
JP2024542188A5
JP2024542188A5 JP2024529348A JP2024529348A JP2024542188A5 JP 2024542188 A5 JP2024542188 A5 JP 2024542188A5 JP 2024529348 A JP2024529348 A JP 2024529348A JP 2024529348 A JP2024529348 A JP 2024529348A JP 2024542188 A5 JP2024542188 A5 JP 2024542188A5
Authority
JP
Japan
Prior art keywords
branched
independently
alkyl
compound according
unbranched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050111 external-priority patent/WO2023091490A1/en
Publication of JP2024542188A publication Critical patent/JP2024542188A/ja
Publication of JP2024542188A5 publication Critical patent/JP2024542188A5/ja
Pending legal-status Critical Current

Links

JP2024529348A 2021-11-16 2022-11-16 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法 Pending JP2024542188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163264149P 2021-11-16 2021-11-16
US63/264,149 2021-11-16
PCT/US2022/050111 WO2023091490A1 (en) 2021-11-16 2022-11-16 Novel ionizable lipids and lipid nanoparticles and methods of using the same

Publications (2)

Publication Number Publication Date
JP2024542188A JP2024542188A (ja) 2024-11-13
JP2024542188A5 true JP2024542188A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=84537194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529348A Pending JP2024542188A (ja) 2021-11-16 2022-11-16 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法

Country Status (9)

Country Link
US (1) US20250049948A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433450A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542188A (cg-RX-API-DMAC7.html)
KR (1) KR20240122774A (cg-RX-API-DMAC7.html)
CN (1) CN118829625A (cg-RX-API-DMAC7.html)
AU (1) AU2022394985A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238292A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005970A (cg-RX-API-DMAC7.html)
WO (1) WO2023091490A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
JP2026521725A (ja) * 2023-06-16 2026-07-01 アクイタス セラピューティクス インコーポレイテッド アミド含有脂質
CN117185942B (zh) * 2023-07-04 2025-09-12 清华大学 一种可用于靶向肺部递送广谱中和抗体的脂质纳米颗粒及其制备方法与应用
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
TW202541819A (zh) 2023-12-27 2025-11-01 日商安斯泰來製藥股份有限公司 脊髓損傷之治療用醫藥組成物及脊髓損傷之非人類靈長類動物模式之製作方法
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2026029046A1 (ja) * 2024-07-30 2026-02-05 アステラス製薬株式会社 側鎖に環状基を有するウレア又はカーバメート脂質、その脂質ナノ粒子、及びその医薬組成物
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026109749A1 (en) * 2024-11-24 2026-05-28 Neovac Ltd. Ionizable lipids suitable for nucleic acid delivery
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system
WO2026152164A1 (en) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079963B1 (en) 1981-06-04 1986-08-27 Delaware Chemicals Corporation Pressurized container with dispensing pump
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
JP2002502831A (ja) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換peg化脂質
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019089828A1 (en) * 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
TWI918825B (zh) * 2021-02-10 2026-03-21 美商艾勒維生技公司 化合物、組合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2024542260A5 (cg-RX-API-DMAC7.html)
JP2022505234A5 (cg-RX-API-DMAC7.html)
TWI699354B (zh) 陽離子性脂質
JP2024546951A5 (cg-RX-API-DMAC7.html)
JP2023164871A5 (cg-RX-API-DMAC7.html)
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
ES2926075T3 (es) Lípido catiónico
JP2024542188A (ja) 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
PE20210655A1 (es) Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
JP2025510229A5 (cg-RX-API-DMAC7.html)
JP2007501185A5 (cg-RX-API-DMAC7.html)
JP2013531634A (ja) オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
JP2018524339A5 (cg-RX-API-DMAC7.html)
JP2022533069A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2009114205A (ja) 心臓血管系および中枢神経系の特定疾病を治療するための縮合(ヘタリール置換)1−ベンジル−3−ピラゾール誘導体の使用
JP2003502405A5 (cg-RX-API-DMAC7.html)
JP2023541427A (ja) 骨格筋送達プラットフォーム及び使用方法
JP2023538524A5 (cg-RX-API-DMAC7.html)
JP2023518944A5 (cg-RX-API-DMAC7.html)
RU2319692C2 (ru) Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты)
JP2010507722A (ja) 標的化リガンドを固定化するための改良型リンカー
JP2021165281A (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2024543272A5 (cg-RX-API-DMAC7.html)
JP2024512770A (ja) 遺伝子送達における非ウイルスベクターとしての樹状構造